Research programme: heat shock protein 90 inhibitors - Serenex

Drug Profile

Research programme: heat shock protein 90 inhibitors - Serenex

Alternative Names: PF-04928473; PF-4928473; SNX 0723; SNX 2112; SNX-3133; SNX-5542

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Serenex
  • Developer Pfizer; Serenex
  • Class Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Breast cancer; Cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top